Trial Profile

A Clinical Study to Evaluate Safety and Efficacy of C-CAR031 Armored CAR-T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs C CAR 031 (Primary)
Indications Liver cancer
Focus Adverse reactions; First in man

Most Recent Events

23 Jul 2026 According to an AbelZeta Pharma media release, this study was led by The First Affiliated Hospital, Zhejiang University School of Medicine's Dr. Tingbo Liang and Dr. Qi Zhang with the support of AbelZeta.
23 Jul 2026 Results presented in the AbelZeta Pharma Media Release.
23 Jul 2026 According to an AbelZeta Pharma media release, company announced a publication in Nature sharing the results of the first-in-human clinical study evaluating the safety and efficacy of C-CAR031.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com